Discover results from the ODYSSEY OUTCOMES trial conducted in post-acute coronary syndrome (ACS) patients

Explore

View alirocumab dose titration and the ODYSSEY OUTCOMES treat-to-target approach

Explore

Learn about the primary end point MACE and additional CV end points in the overall trial population

Explore

Learn about the results on MACE in high risk patients (baseline LDL-C ≥ 2.6 mmol/L)

Explore

Select ODYSSEY OUTCOMES publications

 
 
 
 
 

ODYSSEY OUTCOMES rationale and study design

Schwartz GG, et al. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. Am Heart J. 2014;168(5):682-689.

ODYSSEY OUTCOMES
primary manuscript

Schwartz GG et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018;379(22):2097-2107.

Total events sub-analysis

Szarek M, et al. Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES Trial. J Am Coll Cardiol. 2019;73(4):387-396.

ACS and polyvascular disease sub-analysis

Jukema JW, et al. Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome: ODYSSEY OUTCOMES Trial. J Am Coll Cardiol. 2019;74(9):1167-1176.

ACS and mortality sub-analysis

Steg PG, et al. Effect of Alirocumab on Mortality After Acute Coronary Syndromes: An Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial. Circulation. 2019;140(2):103-112.

We’ve researched far and wide to collect the results for ODYSSEY OUTCOMES, a cardiovascular outcomes trial with alirocumab (a PCSK9 inhibitor).